Your browser doesn't support javascript.
Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study.
Collard, Didier; Nurmohamed, Nick S; Kaiser, Yannick; Reeskamp, Laurens F; Dormans, Tom; Moeniralam, Hazra; Simsek, Suat; Douma, Renee; Eerens, Annet; Reidinga, Auke C; Elbers, Paul W G; Beudel, Martijn; Vogt, Liffert; Stroes, Erik S G; van den Born, Bert-Jan H.
  • Collard D; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Nurmohamed NS; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Kaiser Y; Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Reeskamp LF; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Dormans T; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Moeniralam H; Department of Intensive Care, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, The Netherlands.
  • Simsek S; Internal Medicine, Sint Antonius Hospital, Nieuwegein, The Netherlands.
  • Douma R; Department of Internal Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.
  • Eerens A; Internal Medicine, Flevoziekenhuis, Almere, Flevoland, The Netherlands.
  • Reidinga AC; Oncology, Treant Healthcare Group, Amsterdam, The Netherlands.
  • Elbers PWG; Intensive Care, Martini Ziekenhuis, Groningen, Groningen, The Netherlands.
  • Beudel M; Department of Intensive Care, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Vogt L; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Stroes ESG; Department of Nephrology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • van den Born BH; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
BMJ Open ; 11(2): e045482, 2021 02 22.
Article in English | MEDLINE | ID: covidwho-1096995
ABSTRACT

OBJECTIVES:

Recent reports suggest a high prevalence of hypertension and diabetes in COVID-19 patients, but the role of cardiovascular disease (CVD) risk factors in the clinical course of COVID-19 is unknown. We evaluated the time-to-event relationship between hypertension, dyslipidaemia, diabetes and COVID-19 outcomes.

DESIGN:

We analysed data from the prospective Dutch CovidPredict cohort, an ongoing prospective study of patients admitted for COVID-19 infection.

SETTING:

Patients from eight participating hospitals, including two university hospitals from the CovidPredict cohort were included.

PARTICIPANTS:

Admitted, adult patients with a positive COVID-19 PCR or high suspicion based on CT-imaging of the thorax. Patients were followed for major outcomes during the hospitalisation. CVD risk factors were established via home medication lists and divided in antihypertensives, lipid-lowering therapy and antidiabetics. PRIMARY AND SECONDARY OUTCOMES

MEASURES:

The primary outcome was mortality during the first 21 days following admission, secondary outcomes consisted of intensive care unit (ICU) admission and ICU mortality. Kaplan-Meier and Cox regression analyses were used to determine the association with CVD risk factors.

RESULTS:

We included 1604 patients with a mean age of 66±15 of whom 60.5% were men. Antihypertensives, lipid-lowering therapy and antidiabetics were used by 45%, 34.7% and 22.1% of patients. After 21-days of follow-up; 19.2% of the patients had died or were discharged for palliative care. Cox regression analysis after adjustment for age and sex showed that the presence of ≥2 risk factors was associated with increased mortality risk (HR 1.52, 95% CI 1.15 to 2.02), but not with ICU admission. Moreover, the use of ≥2 antidiabetics and ≥2 antihypertensives was associated with mortality independent of age and sex with HRs of, respectively, 2.09 (95% CI 1.55 to 2.80) and 1.46 (95% CI 1.11 to 1.91).

CONCLUSIONS:

The accumulation of hypertension, dyslipidaemia and diabetes leads to a stepwise increased risk for short-term mortality in hospitalised COVID-19 patients independent of age and sex. Further studies investigating how these risk factors disproportionately affect COVID-19 patients are warranted.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart Disease Risk Factors / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2020-045482

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart Disease Risk Factors / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2020-045482